Business development

Cantargia’s business model and scientific strategy are based on partnerships and Cantargia has established agreements with several companies, hospitals, and academic research groups. 

Currently, around 50 international and local players are involved with research and development related to Cantargia’s lead asset, nadunolimab (CAN04), as well as the CAN10 project.